| Renal cell carcinoma treatment | Lifetime | 2 | US 2 | 99.97 |
| Renal and related cancers | Lifetime | 2 | US 2 | 99.95 |
| Cancer Genomics and Diagnostics | Lifetime | 7 | US 5 | 99.95 |
| Ferroptosis and cancer prognosis | Lifetime | 3 | US 1 | 99.87 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 11 | US 8 | 99.86 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 18 | US 11 | 99.94 |
| Economic and Financial Impacts of Cancer | Lifetime | 4 | US 4 | 99.86 |
| COVID-19 and healthcare impacts | Lifetime | 17 | US 5 | 99.38 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 40 | US 27 | 99.83 |
| Multiple and Secondary Primary Cancers | Lifetime | 16 | US 6 | 99.71 |
| Cancer Diagnosis and Treatment | Lifetime | 66 | US 38 | 99.39 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 313 | US 155 | 99.06 |
| Prostate Cancer Treatment and Research | Lifetime | 315 | US 183 | 99.04 |
| Urinary and Genital Oncology Studies | Lifetime | 190 | US 110 | 98.63 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 460 | US 233 | 98.54 |
| Cancer, Lipids, and Metabolism | Lifetime | 563 | US 279 | 97.93 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 122 | US 69 | 97.13 |
| CAR-T cell therapy research | Lifetime | 869 | US 500 | 97.74 |
| Vascular Tumors and Angiosarcomas | Lifetime | 376 | US 197 | 95.45 |
| Phagocytosis and Immune Regulation | Lifetime | 788 | US 317 | 90.39 |
| Cancer Genomics and Diagnostics | 2021-2025 | 2 | US 1 | 99.96 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 3 | US 1 | 99.98 |
| Renal cell carcinoma treatment | 2021-2025 | 1 | US 1 | 99.99 |
| Renal and related cancers | 2021-2025 | 1 | US 1 | 99.99 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 5 | US 2 | 99.86 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 3 | US 3 | 99.78 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 6 | US 2 | 99.84 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 10 | US 4 | 99.26 |
| COVID-19 and healthcare impacts | 2021-2025 | 72 | US 29 | 98.03 |
| Ferroptosis and cancer prognosis | 2021-2025 | 121 | US 15 | 97.78 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 27 | US 14 | 96.28 |
| Epigenetics and DNA Methylation | 2021-2025 | 346 | US 112 | 94.66 |
| Cancer Research and Treatments | 2021-2025 | 272 | US 72 | 89.26 |
| Phagocytosis and Immune Regulation | 2021-2025 | 320 | US 99 | 79.07 |
| Cancer Diagnosis and Treatment | 2021-2025 | 635 | US 151 | 78.54 |
| Cardiac tumors and thrombi | 2021-2025 | 728 | US 231 | 71.34 |
| Healthcare cost, quality, practices | 2021-2025 | 972 | US 406 | 68.79 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 947 | US 304 | 52.66 |
